[1]
L. Gheorghe, “Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy”, JGLD, vol. 31, no. 4, pp. 437-443, Dec. 2022.